Two protease inhibitor switch studies show longer virologic response in patients switching to a regimen containing Sustiva.
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D004334:Drug Administration Schedule; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D010078:Oxazines / Q000008:administration & dosage / Q000627:therapeutic use*; D010349:Patient Compliance; D016032:Randomized Controlled Trials as Topic; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz